Medpace Holdings, Inc. $MEDP Shares Sold by Swedbank AB

Swedbank AB lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 62.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 22,000 shares of the company’s stock after selling 36,000 shares during the period. Swedbank AB’s holdings in Medpace were worth $12,356,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Optiver Holding B.V. acquired a new position in shares of Medpace in the 3rd quarter valued at $27,000. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Medpace in the 4th quarter valued at $30,000. Elyxium Wealth LLC acquired a new position in shares of Medpace in the 4th quarter valued at $30,000. Finally, Quarry LP acquired a new position in shares of Medpace in the 3rd quarter valued at $35,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Neutral Sentiment: Multiple law firms, including Rosen, Faruqi & Faruqi, Pomerantz, and others, reiterated reminders about the pending Medpace securities class action and the June 8 lead-plaintiff deadline. Article Title
• Neutral Sentiment: The class action centers on claims that Medpace overstated demand metrics and understated cancellations during the April 22, 2025 to February 9, 2026 class period. Article Title
• Negative Sentiment: The steady stream of litigation alerts adds uncertainty around potential settlement costs and legal distraction, which can pressure MEDP shares even without new operational news. Article Title

Medpace Price Performance

Shares of NASDAQ MEDP opened at $429.11 on Wednesday. The stock’s 50-day moving average is $458.28 and its two-hundred day moving average is $516.59. Medpace Holdings, Inc. has a 1-year low of $291.28 and a 1-year high of $628.92. The company has a market cap of $12.26 billion, a price-to-earnings ratio of 26.97, a price-to-earnings-growth ratio of 2.20 and a beta of 1.19.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same quarter in the prior year, the business earned $3.67 EPS. Medpace’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 20.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several recent analyst reports. Leerink Partners decreased their price target on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 11th. BMO Capital Markets decreased their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Barclays decreased their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Weiss Ratings lowered Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Finally, Robert W. Baird decreased their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $467.08.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.